Literature DB >> 2702395

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.

R T Oliver1, A B Nethersell, J M Bottomley.   

Abstract

A series of 73 patients with measurable metastatic disease referred to a tertiary referral centre for consideration for an experimental treatment protocol were entered into a surveillance protocol in order to establish the incidence of spontaneous regression. Initially, patients were taken off the study if metastases showed greater than 25% increase in products of bidimensional measurement but with increasing confidence patients went into therapy protocols only following the development of symptomatic progression. We observed 3 complete and 2 partial unexplained spontaneous regressions and a further 4 patients had prolonged stable disease for more than 12 months. A group of 21 patients on progression subsequently received treatment with alpha-interferon (Wellferon) as part of a multicentre study which included an additional 61 cases; 12 responded (3 surveillance relapse patients and 9 others). Patients with lung metastases only had the highest response rate (10/17 compared with 5 unexplained responses seen in 38 such patients on surveillance). These results confirm that alpha-interferon is active against metastatic renal carcinoma and that the responses are not totally explicable by spontaneous regression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702395     DOI: 10.1111/j.1464-410x.1989.tb05147.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  33 in total

1.  Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review.

Authors:  Christina Canil; Sebastien Hotte; Linda A Mayhew; Tricia S Waldron; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

2.  High-dose vitamin C therapy: renewed hope or false promise?

Authors:  Sarit Assouline; Wilson H Miller
Journal:  CMAJ       Date:  2006-03-28       Impact factor: 8.262

3.  New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer.

Authors:  Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 4.  Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.

Authors:  Mamta Parikh; Poornima Bajwa
Journal:  Semin Nephrol       Date:  2020-01       Impact factor: 5.299

5.  Activity of a short course of interferon alpha for metastatic renal cell carcinoma--a phase-2 study.

Authors:  R P Abratt; A R Pontin; H S Ball
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 6.  Allogeneic stem-cell transplantation in renal-cell carcinoma.

Authors:  B M Hayes-Lattin; R T Maziarz; T M Beer
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 7.  The application of high-dose interleukin-2 for metastatic renal cell carcinoma.

Authors:  David F McDermott
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

8.  A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Authors:  B Gaugler; N Brouwenstijn; V Vantomme; J P Szikora; C W Van der Spek; J J Patard; T Boon; P Schrier; B J Van den Eynde
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 9.  Advanced renal cell carcinoma.

Authors:  B G Redman; A E Chang
Journal:  Curr Treat Options Oncol       Date:  2000-12

10.  Sunitinib for advanced renal cell cancer.

Authors:  Chris Coppin
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.